Impaired anti‐inflammatory efficacy of n‐butyrate in patients with IBD

Eur J Clin Invest 2011; 41 (3): 291–298

[1]  D. Moher,et al.  A catalogue of reporting guidelines for health research , 2010, European journal of clinical investigation.

[2]  H. Clevers.  Inflammatory bowel disease, stress, and the endoplasmic reticulum. , 2009, The New England journal of medicine.

[3]  W. Strober.  The multifaceted influence of the mucosal microflora on mucosal dendritic cell responses. , 2009, Immunity.

[4]  M. Neurath,et al.  Translating inflammatory bowel disease research into clinical medicine. , 2009, Immunity.

[5]  T. Sweeting,et al.  Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease , 2009, The Journal of experimental medicine.

[6]  G. Gerken,et al.  Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. , 2009, Gastroenterology.

[7]  W. Sandborn.  Current directions in IBD therapy: what goals are feasible with biological modifiers? , 2008, Gastroenterology.

[8]  D. Jonkers,et al.  Review article: the role of butyrate on colonic function , 2007, Alimentary pharmacology & therapeutics.

[9]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[10]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[11]  P. Marteau.  Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease? , 2006, Gut.

[12]  F. Powrie,et al.  Interleukin-23 drives innate and T cell–mediated intestinal inflammation , 2006, The Journal of experimental medicine.

[13]  Bernhard Radlwimmer,et al.  A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. , 2006, American journal of human genetics.

[14]  U. Turunen,et al.  Family and twin studies in inflammatory bowel disease. , 2006, World journal of gastroenterology.

[15]  P. Rutgeerts,et al.  Toll‐like receptor‐1, ‐2, and ‐6 polymorphisms influence disease extension in inflammatory bowel diseases , 2006, Inflammatory bowel diseases.

[16]  C. Elson,et al.  Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota , 2005, Immunological reviews.

[17]  M. Neurath,et al.  Anti-interleukin-12 antibody for active Crohn's disease. , 2004, The New England journal of medicine.

[18]  W. Scheppach,et al.  The butyrate story: old wine in new bottles? , 2004, Current opinion in clinical nutrition and metabolic care.

[19]  B. Franke,et al.  NOD2 mediates anti‐inflammatory signals induced by TLR2 ligands: implications for Crohn's disease , 2004, European journal of immunology.

[20]  L. Steidler.  Genetically engineered probiotics. , 2003, Best practice & research. Clinical gastroenterology.

[21]  G. Bouma,et al.  The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.

[22]  V. Annese,et al.  Topical butyrate improves efficacy of 5‐ASA in refractory distal ulcerative colitis: results of a multicentre trial , 2003, European journal of clinical investigation.

[23]  P. Jeannesson,et al.  Butyrate affects differentiation, maturation and function of human monocyte‐derived dendritic cells and macrophages , 2002, Clinical and experimental immunology.

[24]  A. Andoh,et al.  In vitro alterations in fecal short chain fatty acids and organic anions induced by the destruction of intestinal microflora under hypotonic and aerobic conditions. , 2002, International journal of molecular medicine.

[25]  M. Säemann,et al.  Short-chain fatty acids: bacterial mediators of a balanced host-microbial relationship in the human gut. , 2002, Wiener klinische Wochenschrift.

[26]  K. Stuhlmeier,et al.  Bacterial metabolite interference with maturation of human monocyte‐derived dendritic cells , 2002, Journal of leukocyte biology.

[27]  P. Clifton,et al.  Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. , 2001, Physiological reviews.

[28]  V. Stigliano,et al.  Topical butyrate for acute radiation proctitis: randomised, crossover trial , 2000, The Lancet.

[29]  W. Hörl,et al.  Anti‐inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL‐12 and up‐regulation of IL‐10 production , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  S. Bakos,et al.  IL-10 Secretion and Sensitivity in Normal Human Intestine and Inflammatory Bowel Disease , 2000, Journal of Clinical Immunology.

[31]  A. Andoh,et al.  Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. , 1999, JPEN. Journal of parenteral and enteral nutrition.

[32]  D. Brenner,et al.  TNF Receptor-Associated Factor-2 Is Involved in Both IL-1β and TNF-α Signaling Cascades Leading to NF-κB Activation and IL-8 Expression in Human Intestinal Epithelial Cells , 1999, The Journal of Immunology.

[33]  F. Pallone,et al.  Interleukin 12 and Th1 responses in inflammatory bowel disease , 1998, Gut.

[34]  C. Fiocchi.  Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[35]  R. Pounder,et al.  A simple clinical colitis activity index , 1998, Gut.

[36]  O. Nielsen,et al.  Involvement of interleukin-4 and -10 in inflammatory bowel disease , 1996, Digestive Diseases and Sciences.

[37]  V. Dalal,et al.  Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. , 1996, Gut.

[38]  J. Patz,et al.  Treatment of refractory distal ulcerative colitis with short chain fatty acid enemas. , 1996, The American journal of gastroenterology.

[39]  G. Greenberg,et al.  Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. , 1994, The American journal of gastroenterology.

[40]  R. Macdermott,et al.  Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease , 1993 .

[41]  T. Kirchner,et al.  Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. , 1992, Gastroenterology.

[42]  W. Roediger.  Utilization of nutrients by isolated epithelial cells of the rat colon. , 1982, Gastroenterology.

[43]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[44]  E. Szigethy,et al.  Inflammatory bowel disease. , 2011, Pediatric clinics of North America.

[45]  Christopher G. Mathew,et al.  New links to the pathogenesis of Crohn disease provided by genome-wide association scans , 2008, Nature Reviews Genetics.

[46]  S. Khader,et al.  IL-12p40: an inherently agonistic cytokine. , 2007, Trends in immunology.

[47]  C. Paraskeva,et al.  A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. , 2000, Carcinogenesis.

[48]  D. Brenner,et al.  TNF receptor-associated factor-2 is involved in both IL-1 beta and TNF-alpha signaling cascades leading to NF-kappa B activation and IL-8 expression in human intestinal epithelial cells. , 1999, Journal of immunology.

[49]  S. Schreiber,et al.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. , 1993, Clinical and experimental immunology.